Institutional equity analysts tracking Aurobindo Pharma project a 12-month consensus share price target range between Rs 1,350 and Rs 1,550, with optimistic bull-case estimates reaching up to Rs 1,900. These valuations are supported by steady international generic expansion, robust injectable manufacturing capacity growth, and new product ramps across European and North American regulated pharmaceutical markets.